$7.12
2.47% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
IE000GID8VI0
Symbol
GHRS
Sector
Industry

GH Research PLC Stock price

$7.12
-2.16 23.28% 1M
-4.87 40.62% 6M
+1.32 22.76% YTD
+1.62 29.45% 1Y
-16.59 69.97% 3Y
-12.13 63.01% 5Y
-12.13 63.01% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.18 2.47%
ISIN
IE000GID8VI0
Symbol
GHRS
Sector
Industry

Key metrics

Market capitalization $370.44m
Enterprise Value $221.13m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.96
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-48.48m
Free Cash Flow (TTM) Free Cash Flow $-39.96m
Cash position $150.04m
EPS (TTM) EPS $-0.80
P/E forward negative
Short interest 12.89%
Show more

Is GH Research PLC a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

GH Research PLC Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a GH Research PLC forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a GH Research PLC forecast:

Buy
100%

Financial data from GH Research PLC

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.32 0.32
28% 28%
-
-0.32 -0.32
28% 28%
-
- Selling and Administrative Expenses 13 13
24% 24%
-
- Research and Development Expense 35 35
23% 23%
-
-48 -48
24% 24%
-
- Depreciation and Amortization 0.32 0.32
28% 28%
-
EBIT (Operating Income) EBIT -48 -48
24% 24%
-
Net Profit -41 -41
1% 1%
-

In millions USD.

Don't miss a Thing! We will send you all news about GH Research PLC directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

GH Research PLC Stock News

Neutral
GlobeNewsWire
about one month ago
DUBLIN, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2024, and provided updates on its business.
Positive
MarketBeat
about 2 months ago
Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside potential at an opportune moment. Certainly, achieving this goal is easier said than done, and there is no guarantee that a company expected to make sizable gains will follow through on that promise.
Neutral
GlobeNewsWire
4 months ago
DUBLIN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2024, and provided updates on its business.
More GH Research PLC News

Company Profile

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. It develops therapeutic products for the patients who are suffering from Treatment Resistant Depression (TRD). The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Villy Valcheva
Employees 49
Founded 2021
Website www.ghres.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today